The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000556347p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
6/03/2026
Date registered
Help: Date registered
1/05/2026
Date last updated
Help: Date last updated
24/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Artificial Intelligence-Driven Hearing Aids for Auditory Neural Disorders for individuals 12 years and above
Scientific title
Effectiveness of Deep Neural Network–Based Hearing Aids on Functional Hearing Outcomes in Participants Aged 12 Years and Older with Auditory Neuropathy
Additional trial identifiers [1] 316712 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
auditory neuropathy 340984 0
auditory neuropathy spectrum disorder 340985 0
auditory synaptopathy 340986 0
Condition category
Condition code
Ear 337129 337129 0 0
Other ear disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study will evaluate TGA-approved Deep neural network (DNN)-enabled hearing aids to address listening challenges in individuals with auditory neuropathy. DNN-enabled aids will also be compared to conventional directional microphone hearing aids.

DNN hearing aids use artificial intelligence to process and enhance speech signals in complex acoustic environments, such as classrooms, by effectively separating speech from background noise.

In comparison, directional microphone hearing aids rely on beam-forming technology to focus on sound from a specific direction (usually in front of the listener) while reducing background noise.

The hearing aids will be setup based on each participant's hearing thresholds. For participants identified to have elevated sound detection levels, hearing aids will be fit to National Acoustic Laboratory Non-linear 2 prescription targets. Real ear measures will be used to verify the aids are matching to prescription targets. For participants with auditory neuropathy but normal hearing thresholds, minimal amplification will be provided (5-10 dB between 1 - 8kHz). Additionally, maximum power output of aids will be reduced to ensure no sounds will be too loud for listener's with normal sound detection thresholds.

For all participants, these hearing aids will be used during two key contexts: (1) laboratory testing and an (2) eight-week take-home trial.

1. In the laboratory-based assessment, Individuals with auditory neuropathy will take part in structured auditory tests, administered by a Research Audiologist, to measure their ability to attend to and understand speech in challenging listening environments. Participants will be asked to perform 2 tasks unaided (no device) and while wearing the devices (aided):

1.1 Speech perception in noise. For this task participants will need to listen to and repeat target sentences (AzBio sentences), which will be played sequentially from 2 loudspeakers positioned at 0 and 90 degrees azimuth while competing background noise (multi-talker babble) is played from 4 loudspeakers positioned in the corners of the room). The stimuli will be delivered at a signal to noise ratio of +5dB and the participant will be seated in the centre of the room. This will take approximately 30 mins for all conditions (unaided, with DNN-based hearing aids and with directional microphone hearing aids).

1.2 Ability to locate sounds. This will require the participants to sit in the middle of a 16-channel loudspeaker array and pinpoint which of the speakers are producing a sound. This will take approximately 30 mins for all conditions.

2. During the take-home hearing aid trial, participants will use two types of hearing aids — traditional directional microphone devices and advanced DNN-enabled hearing aids over an eight-week period (total). Participants will be encouraged to wear the devices as much as possible. Each device will be worn for four weeks, allowing participants to experience its benefits in real-world environments such as school (if applicable), home, or social settings. At baseline and at the end of each four-week trial, participants will complete a short set of self-administered questionnaires (including the Speech, Spatial and Qualities of Hearing questionnaire and the Abbreviated Profile of Hearing aid Benefit questionnaire) that captures perceptions of the hearing devices in daily life. It will take approximately 20 mins to complete the questionnaires. Device adherence will be monitored using the datalogging feature of the hearing aids, which provide an indication of the hours per day the hearing aids are worn. No washout period will be used in the study.

A washout period will not be used in this study because the interventions being tested, DNN-hearing aids and traditional directional microphone hearing aids are non-pharmacological and do not have lingering physiological effects that could influence subsequent testing. The devices function only when actively worn and are removed at the end of each testing session or daily use. Unlike pharmacological interventions, hearing aids do not leave residual effects that could interfere with participants’ performance in future testing or with the alternative device.

Additionally, the study design ensures each device is tested over a four-week period during the take-home trial, which allows participants sufficient time to become familiar with each hearing aid type. During the laboratory-based testing sessions, a randomised testing order will ensure unbiased comparisons between the devices. Since there is no physiological carryover between conditions, a washout period is unnecessary and would only increase the burden on participants without adding scientific value to the study.

These interventions aim to identify which hearing aid technology offers superior outcomes for individuals with auditory neuropathy.
Intervention code [1] 333397 0
Rehabilitation
Intervention code [2] 333838 0
Treatment: Devices
Description of the comparator or control
DNN-enabled hearing aids will be compared against (i) no intervention or currently used intervention and (ii) 'traditional' hearing aids with directional microphone technology.

Potential benefits will be assessed in individuals diagnosed with auditory neuropathy. A control group of gender, age and hearing level matched peers will also be included. This group will also complete both the auditory laboratory assessments and the 8-week trial.

A washout period will not be used in this study because the interventions being tested, DNN-hearing aids and traditional directional microphone hearing aids, are non-pharmacological and do not have lingering physiological effects that could influence subsequent testing. The devices function only when actively worn and are removed at the end of each testing session or daily use. Unlike pharmacological interventions, hearing aids do not leave residual effects that could interfere with participants’ performance in future testing or with the alternative device.
Control group
Active

Outcomes
Primary outcome [1] 344641 0
Functional hearing ability
Timepoint [1] 344641 0
Baseline and after each device trial (e.g. end of 2 and 4 weeks).
Primary outcome [2] 344642 0
Functional hearing ability
Timepoint [2] 344642 0
Baseline and after each device trial (e.g. end of 2 and 4 weeks).
Secondary outcome [1] 458720 0
Localisation
Timepoint [1] 458720 0
Baseline unaided (10 mins), with DNN-hearing aids (10 mins) and with directional microphone hearing aids (10 mins). This will enable a comparison in the ability for this task between interventions.
Secondary outcome [2] 458721 0
Speech Perception
Timepoint [2] 458721 0
Baseline unaided (15 mins), with DNN-hearing aids (15 mins) and with directional microphone hearing aids (15 mins). This will enable a comparison in the ability for this task between interventions.

Eligibility
Key inclusion criteria
Inclusion criteria for the auditory neuropathy (AN) group:
1. Age 12–17 years (paediatric cohort) or 18-65 years (adult cohort).
2. Clinical diagnosis of AN indicated by:
- Absent/abnormal ABR consistent with AN, and
- Present OAE and/or cochlear microphonic (current or documented historically).
- Able to complete speech testing in English, and comply with study procedures.

Inclusion criteria for the control group:
Age- and sex-matched participants with sensorineural hearing loss not consistent with AN (i.e. normal ABR consistent with cochlear HL), matched on hearing thresholds and hearing configuration, no history of auditory processing disorders, and neurologically normal.
Minimum age
12 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion criteria:
1. The presence of an active external and/or middle ear pathology. Individuals with conditions such as untreated otitis media would be excluded, as these factors could interfere with the hearing aid fitting procedure. This will be determined using a case history, otoscopic examination and tympanometry (if warranted).
2.Individuals fitted with a cochlear implant
3. Individuals unable to wear a behind-the-ear hearing aid (i.e. individuals with anotia/microtia)
4. Inability to provide consent/assent or comply with protocol.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table from a statistic book
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321316 0
Commercial sector/Industry
Name [1] 321316 0
SONOVA AG
Country [1] 321316 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324495 0
None
Name [1] 324495 0
Address [1] 324495 0
Country [1] 324495 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 319847 0
University of Melbourne Central Human Research Ethics Committee
Ethics committee address [1] 319847 0
Ethics committee country [1] 319847 0
Australia
Date submitted for ethics approval [1] 319847 0
15/04/2026
Approval date [1] 319847 0
Ethics approval number [1] 319847 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148602 0
Dr Julien Zanin
Address 148602 0
University of Melbourne, Department of Audiology and Speech Pathology, 550 Swanston St, Carlton, VIC 3053
Country 148602 0
Australia
Phone 148602 0
+61383445303
Fax 148602 0
Email 148602 0
Contact person for public queries
Name 148603 0
Julien Zanin
Address 148603 0
University of Melbourne, Department of Audiology and Speech Pathology, 550 Swanston St, Carlton, VIC 3053
Country 148603 0
Australia
Phone 148603 0
+61383445303
Fax 148603 0
Email 148603 0
Contact person for scientific queries
Name 148604 0
Julien Zanin
Address 148604 0
University of Melbourne, Department of Audiology and Speech Pathology, 550 Swanston St, Carlton, VIC 3053
Country 148604 0
Australia
Phone 148604 0
+61383445303
Fax 148604 0
Email 148604 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.